PEG & ADCs
- Global Sales of Antibody-drug Conjugates (ADCs) in 2024
- Global Sales of ADCs in 2023 – UP to 10 Billion
- FDA Approves Datroway (Datopotamab Deruxtecan) in HR+/HER2– Breast Cancer
- Radionuclide Drug Conjugates (RDCs): Current Status
- Antibody–Drug Conjugates Targeting MUC1
- ADC in Combination with PD-1: Approvals and Clinical Trials
- Summary of Approved HER2 ADCs on The Market & in Clinical Trials
- The Rise of the TROP2-Directed ADCs for Solid Tumors
- Development of Current Four Generation ADCs And Next Generation ADCs
- ADC Drugs: Some Challenges To Be Solved